Accession Number : ADA597779


Title :   A Placebo-Controlled Augmentation Trial of Prazosin for Combat Trauma PTSD


Descriptive Note : Revised final rept. 1 Jun 2008-31 May 2013


Corporate Author : SEATTLE INST FOR BIOMEDICAL AND CLINICAL RESEARCH SEATTLE WA


Personal Author(s) : Raskind, Murray


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a597779.pdf


Report Date : Aug 2013


Pagination or Media Count : 15


Abstract : Trauma content nightmares and sleep disturbance are among the most distressing and debilitating symptoms of military posttraumatic stress disorder (PTSD). We performed a randomized placebo-controlled trial of prazosin, a brain-active alpha-1 adrenoreceptor antagonist, for PTSD nightmares, sleep disturbance, ability to function, and overall PTSD severity in 67 active duty Service Members returned from combat deployments in Iraq and Afghanistan and stationed at Joint Base Lewis- McChord, Washington. Prazosin or placebo were titrated upward over six weeks guided by trauma nightmare reduction. Achieved doses were continued for an additional nine weeks. Mean achieved prazosin doses were 4.0 +/- 1.4 mg at midmorning and 15.6 +/- 6.0 at bedtime. Prazosin was significantly superior to placebo for reducing trauma nightmares, improving sleep quality, improving global function and reducing total PTSD symptom scores. Prazosin was well tolerated, with no differences between prazosin and placebo on blood pressure or adverse events. These results suggest that prazosin is a useful treatment for combat-induced PTSD in active duty Service Members with distressing nighttime PTSD symptoms.


Descriptors :   *POST TRAUMATIC STRESS DISORDER , AFGHANISTAN , BLOOD PRESSURE , DEPLOYMENT , DOSAGE , DRUGS , IRAQ , ORDER DISORDER TRANSFORMATIONS , SIGNS AND SYMPTOMS , SLEEP


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research
      Stress Physiology


Distribution Statement : APPROVED FOR PUBLIC RELEASE